Navigation Links
Lentigen Corporation Announces Exclusive Licensing Agreement With Case Western Reserve University to Develop Novel Stem-Cell Therapy for Brain Cancer

GAITHERSBURG, Md., March 20 /PRNewswire/ -- Lentigen Corporation today announced an exclusive licensing agreement with Case Western Reserve University (CWRU) in Cleveland, Ohio, to develop a novel stem-cell therapy for glioblastoma, an aggressive type of brain cancer. Under the agreement, Case Western and its primary affiliate, University Hospitals Case Medical Center, will lead the first in vivo clinical trial, and Lentigen will be responsible for further clinical development and commercialization.

The new therapy will be based on MGMT, a gene that has been shown to repair damaged DNA. A specially designed lentiviral vector will be used to deliver the gene specifically to bone-marrow stem cells that have been damaged by drugs commonly used to treat cancer. A Phase I clinical trial, which will be held at Case Western later this year, will evaluate the potential of this lentiviral vector-MGMT technology (LV-MGMT) to enhance current treatments for glioblastoma by repairing and preventing this damage to bone-marrow stem cells.

"This clinical trial will represent the first time lentiviral vectors will be used with MGMT for stem cell therapy in humans," said Stanton L. Gerson, MD, director of the Ireland Cancer Center of University Hospitals Case Medical Center and the Case Comprehensive Cancer Center, who co-developed the technology with Anthony E. Pegg, Ph.D., the Evan Pugh Professor of Cellular and Molecular Physiology, and Pharmacology at Penn State University. Dr. Gerson commented, "Glioblastoma is a serious diagnosis with limited treatment options, so this new therapeutic approach has the potential to greatly enhance options for patients with this terrible disease."

Boro Dropulic, Ph.D., Lentigen's founder, president and chief scientific officer, commented, "LV-MGMT technology has the potential to greatly enhance the therapeutic efficacy of existing drugs that target glioblastoma by lowering their toxicity to bone marrow stem cells. Beyond glioblastoma, this technology could also be used for therapies for other diseases such as AIDS, leukemia and hemophilia. We are quite excited to be working with Dr. Gerson to move LV-MGMT into the clinic."

Tim Ravenscroft, Lentigen's CEO, commented, "We feel very fortunate to be collaborating with Dr. Gerson to develop this promising technology with broad potential applications. Our exclusive license to develop this technology is a significant step towards our goal of applying our lentiviral vector expertise to the development of cutting-edge biotherapeutics."

About Lentiviral Vectors

Lentiviral vectors (LV) are vehicles that can deliver genes or RNAi into cells with up to 100% efficiency and stability. By comparison, other viral vector systems such as non-viral, adenoviral and adeno-associated viral vectors have not been shown to achieve both high and stable gene delivery in dividing cells.

Gene delivery is accomplished by the binding and fusing of the LV pseudotyped envelope protein to the target cell membrane. The LV RNA containing the gene or gene silencing sequence is then incorporated into the cell via reverse transcription creating a DNA complex. This complex enters the nucleus incorporating into the chromosomal DNA creating a stable molecule. The gene sequence is integrated in the chromosome and is copied along with the DNA during ongoing cell division.

About Lentigen Corporation

Lentigen Corporation is a privately owned biotechnology company focused on the development of lentiviral vector technology for a wide range of therapeutic, vaccine and research applications in biotechnology and medicine. Lentiviral vectors are the most efficient vehicles for the delivery of genes or gene silencing sequences stably into cells. Lentigen is a highly collaborative company, co-developing lentiviral vector-based products across a broad spectrum of bench to clinical applications. Partnerships include The National Institutes of Health, The University of Pennsylvania, ThermoFisher Scientific and The U.S. Army. For further information, visit


Gregory Tiberend

Meghan Feeks

Richard Lewis Communications, Inc.


SOURCE Lentigen Corporation
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. VIRxSYS and Lentigen Announce Litigation Settlement
2. Lentigen Appoints Tim Ravenscroft as Chief Executive Officer
3. Lentigen to Move Headquarters and Manufacturing to Gaithersburg
4. Memry Corporation Announces Preliminary Fiscal Fourth Quarter and 2007 Revenue
5. PeriCor Therapeutics Announces Closing of Licensing Agreement for Acadesine with Schering-Plough Corporation
6. AGA Medical Corporation Receives FDA and CE Mark Approvals for the AMPLATZER Vascular Plug II
7. Drug Royalty Corporation (DRC) Announces Acquisition Regarding PEG-INTRON(R) From Enzon Pharmaceuticals, Inc. (ENZN)
8. BioElectronics Corporation Announces Singapore and Malaysia Sales
9. Avicena Signs Worldwide Exclusive Distribution Agreement with RITA Corporation for its Proprietary Dermaceutical Compounds
10. DURECT Corporation to Present at the NewsMakers in the Biotech Industry Investment Conference
11. Insulet Corporation to Present at the Thomas Weisel Partners Healthcare Conference on September 6, 2007
Post Your Comments:
(Date:11/27/2015)... Nov. 27, 2015 /PRNewswire/--  Mallinckrodt plc (NYSE: ... that it has closed the sale of its global ... (GBT- NYSE Euronext) in a transaction valued at approximately ... facilities and a total of approximately 1,000 employees spread ... St. Louis area. This entire workforce ...
(Date:11/26/2015)... CHESHAM , England , November 26, ... Lightpoint Medical, an innovative medical device company specializing in ... Euro grant from the European Commission as part of the ... enabling the company to carry out a large-scale clinical trial ... -->      (Logo: , ...
(Date:11/25/2015)... 2015 Studies reveal the differences ... and pave the way for more effective treatment for one ...   --> --> ... problems in cats, yet relatively little was understood about the ... have been conducted by researchers from the WALTHAM Centre for ...
(Date:11/25/2015)... ... November 25, 2015 , ... A long-standing partnership between the ... has been formalized with the signing of a Memorandum of Understanding. , AMA ... Capt. Karl Minter and Capt. Albert Glenn Tuesday, November 24, 2015, at AMA ...
Breaking Biology Technology:
(Date:11/17/2015)... Nov. 17, 2015  Vigilant Solutions announces today that ... Board of Directors. --> ... retiring from the partnership at TPG Capital, one of ... over $140 Billion in revenue.  He founded and led ... the TPG companies, from 1997 to 2013.  In his ...
(Date:11/12/2015)... 11, 2015   Growing need for low-cost, ... has been paving the way for use of ... discrete analytes in clinical, agricultural, environmental, food and ... used in medical applications, however, their adoption is ... to continuous emphasis on improving product quality and ...
(Date:11/9/2015)...  Synaptics Inc. (NASDAQ: SYNA ), the leading ... into the automotive market with a comprehensive and dedicated ... consumer electronics human interface innovation. Synaptics, industry-leading touch controllers, ... automotive industry and will be implemented in numerous locations ... , Japan , and ...
Breaking Biology News(10 mins):